Lucintel Blog: Lucintel Forecasts High Potency API Market to Reach $28.1 Billion by 2028

Sunday, June 11, 2023

Lucintel Forecasts High Potency API Market to Reach $28.1 Billion by 2028

According to the recent study the high potency API market is projected to reach an estimated $28.1 billion by 2028 from $25.0 billion in 2023, at a CAGR of 8.7 from 2023 to 2028. Growth in this market is primarily driven by growing demand for oncology drugs and antibody-drug conjugates, increasing demand for outsourcing HPAPIs, and growing focus on precision medicine.

A more than 150–page report is developed to understand trends, opportunities and forecast in high potency API market by type of type (innovative API market and generic API market), type of synthesis (synthetic API market and biotech API market), type of manufacturers (captive API market and merchant API market), therapeutic application (oncology, hormonal imbalance, glaucoma, and other therapeutic applications) and others), and region (North America, Europe, Asia Pacific, and the Rest of the World).

Download sample report by clicking on below link

https://www.lucintel.com/high-potency-api-market.aspx

“Synthetic API market is expected to remain the largest segment during the forecast period.”

Based on type of synthesis, the high potency API market is segmented into synthetic API market and biotech API market. Lucintel forecasts that the synthetic API market is expected to remain the largest segment due to a growing number of new APIs and increasing adoption of these APIs in treating a wide range of diseases.

“Within the high potency API market, the oncology segment is expected to remain the largest therapeutic application.”

Based on therapeutic application the oncology segment is expected to witness the highest growth over the forecast period due to increasing cases of cancer across the globe.

“North America will dominate the high potency API market in near future.”

North America is expected to remain the largest region over the forecast period due to growing incidence of chronic diseases and increased awareness of the high potency APIs in the treatment of serious ailments.

Download Brochure of this report by clicking on https://www.lucintel.com/high-potency-api-market.aspx.

Major players of high potency API market are adopting various growth strategies like new product launches, expansions, merger and acquisitions, partnerships, agreements, and collaborations to expand their presence in this market. Pfizer, F. Hoffmann-La Roche, Sanofi, Bristol-Myers Squibb, Bayer AG, Novartis International AG, Boehringer Ingelheim International, Teva Pharmaceutical Industries, Eli Lilly and Company, Merck & Co, AbbVie, and Viatris are among the major high potency API providers.

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link https://www.lucintel.com/high-potency-api-market.aspx or helpdesk@lucintel.com.

About Lucintel

At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times. For further information, visit www.lucintel.com.

Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. 972.636.5056

Related reports

Mhealth Solution Market:

For more details click here https://www.lucintel.com/mhealth-solution-market.aspx

Minimally Invasive Surgery Market:

For more details click here https://www.lucintel.com/minimally-invasive-surgery-market.aspx

Medical Aesthetic Market:

For more details click here https://www.lucintel.com/medical-aesthetic-market.aspx

Neurostimulation Market:

For more details click here https://www.lucintel.com/neurostimulation-market.aspx

Nuclear Medicine/Radiopharmaceutical Market:

For more details click here https://www.lucintel.com/nuclear-medicine-radiopharmaceutical-market.aspx